Imepitoin vs phenobarbital as first-line treatment for canine idiopathic epilepsy — POSSIBLE

In dogs with newly diagnosed idiopathic epilepsy, does imepitoin vs phenobarbital give equal seizure control with fewer adverse effects?

Shelf #288 · gate-verified and approved by the developer

POSSIBLE: Imepitoin controlled seizures comparably to phenobarbital in a blinded parallel-group field study of 226 client-owned dogs, with adverse events including somnolence/sedation, polydipsia and increased appetite significantly more frequent on phenobarbital, and liver-enzyme increases seen on phenobarbital but not imepitoin (Tipold 2015). A separate randomised double-blind dose trial found 30 mg/kg twice daily reduced monthly seizure frequency significantly more than 1 mg/kg twice daily, with the effect maintained over a further 12 weeks (Rundfeldt 2015). Neither record reports a placebo arm or numeric seizure-frequency rates for the head-to-head comparison, so comparable efficacy rests on the trials' own conclusions rather than carded absolute rates — which is what holds this shelf at POSSIBLE. Drafted Nov 10, 2026 (VetMed build, topic #288); all figures from abstracts fetched and verified at drafting.

Tipold 2015: imepitoin showed comparable efficacy to phenobarbital in 226 dogs, with fewer adverse events and no liver-enzyme rise

Blinded parallel-group multicentre field study

Who: Dogs: 226 client-owned dogs with idiopathic epilepsy in a multicentre field efficacy study, comparing imepitoin twice daily in incremental doses of 10, 20 or 30 mg/kg against phenobarbital, in a blinded parallel group design; a separate laboratory safety study in healthy Beagle dogs is also reported in the same record.

Result: The record states imepitoin demonstrated comparable efficacy to phenobarbital in controlling seizures. The frequency of adverse events including somnolence/sedation, polydipsia and increased appetite was significantly higher in the phenobarbital group. In phenobarbital-treated dogs, significantly increased levels of alkaline phosphatase, gamma-glutamyl-transferase and other liver enzymes occurred, while no such effect was observed in the imepitoin group. The abstract reports no numeric seizure-frequency rates for either arm, and none are carded here.

Watch out: The record establishes blinding ('blinded parallel group design') but does not state randomisation in its abstract or publication types, so this card does not call the trial randomised. There is no placebo arm — the comparison is against the established first-line drug — and the headline efficacy claim is qualitative in the record.

Tipold A, Keefe TJ, Löscher W et al. Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs. J Vet Pharmacol Ther. 2015 Apr;38(2):160-8. PMID: 25079881. Registry ID: none in the record. MeSH: Animals · Anticonvulsants · Dog Diseases · Dogs · Dose-Response Relationship, Drug · Epilepsy · Imidazoles · Phenobarbital

Rundfeldt 2015: imepitoin 30 mg/kg twice daily beat 1 mg/kg twice daily on seizure frequency in newly diagnosed dogs

Randomised controlled clinical study, double-blind phase

Who: Dogs: field population of dogs with previously untreated (newly diagnosed) epilepsy, randomised to imepitoin 30 mg/kg twice daily or 1 mg/kg twice daily for 12 weeks under double blind conditions, followed by 12 weeks open label in which all animals received 30 mg/kg twice daily.

Result: Treatment with 30 mg/kg twice daily resulted in a significantly greater reduction in monthly seizure frequency relative to baseline than the 1 mg/kg dose; generalised and partial seizures, but not cluster seizures, were significantly less frequent in the high-dose group. At the end of the open-label phase, 32.1% of dogs in the former high-dose group and 46.8% in the former low-dose group remained free of generalised tonic-clonic seizures. Any adverse drug reactions were more frequent at 30 mg/kg (59% vs 41%, P = 0.041), mainly central nervous system effects, mostly in the first weeks; no hepatic enzyme increase was observed.

Watch out: The comparator is a low dose of the same drug, not phenobarbital or placebo, so this trial establishes dose-dependent antiepileptic activity rather than first-line equivalence; the second phase was open label.

Rundfeldt C, Tipold A, Löscher W. Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up. BMC Vet Res. 2015 Sep 2;11:228. PMID: 26330063. Registry ID: none in the record. MeSH: Animals · Anticonvulsants · Dog Diseases · Dogs · Epilepsy · Female · Imidazoles · Male

Synthesis: a credible first-line alternative to phenobarbital, with a cleaner adverse-event profile in the head-to-head record

Synthesis

Who: Synthesis of the cards above: Tipold 2015 (blinded parallel-group field study, 226 client-owned dogs) and Rundfeldt 2015 (randomised double-blind dose comparison with open-label follow-up).

Result: Together the records support imepitoin as a first-line option whose seizure control the field trial found comparable to phenobarbital, with significantly fewer of the common adverse events and no liver-enzyme signal, and whose antiepileptic activity is dose-dependent against its own low dose. What the records do not provide is a placebo-controlled first-line trial or published absolute seizure rates for the head-to-head, so the stamp stays POSSIBLE.

Watch out: Both programmes are closely tied to the drug's development; independent replication and numeric head-to-head seizure outcomes would be needed to raise the stamp.

Synthesis of Tipold A et al. PMID: 25079881; Rundfeldt C et al. PMID: 26330063. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.